Geee Posted August 11, 2020 Share Posted August 11, 2020 Just the News Members of the National Institutes of Health's COVID-19 Treatment Guidelines Panel have financial ties to a company behind clinical trials of a drug to treat coronavirus, as well as to another large pharmaceutical company involved with developing a COVID-19 vaccine. According to the NIH, members of the panel include U.S. physicians, statisticians, and other experts who are developing treatment guidelines on COVID-19 "intended for healthcare providers." A total of eight panel members list a financial relationship with Gilead Sciences on the panel's Financial Disclosure for Companies Related to COVID-19 Treatment or Diagnostics document: Judith Aberg, MD, Adaora Adimora, MD, Jason Baker, MD, Roger Bedimo, MD, Eric Daar, MD, David V. Glidden, PhD, Susanna Naggie, MD, and Pablo Tebas, MD. The U.S. has reportedly bought almost all of Gilead Sciences' supply of the COVID-19 drug remdesivir. The company announced on June 1 the results of a phase 3 clinical trial of the drug in patients with moderate COVID-19. Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now